PHARMACY

Abbott unveils next-gen point-of-care testing for flu, strep
Abbott's Influenza A & B 2 and Strep A 2 assays combine speed with efficacy for rapid delivery of molecular results at point of care, the company said.
Jazz Pharmaceuticals gets FDA nod for Xyrem for pediatric patients
Jazz Pharmaceuticals' FDA approval of a new indication for Xyrem gives narcolepsy patients age seven years old and older a treatment for cataplexy, or excessive daytime sleepiness,

Mayne to launch halobetasol

Mayne Pharma is planning to launch halobetasol foam, a potent corticosteroid for plaque psoriasis, in early 2019.
Hy-Vee eyes personalization as the next pharmacy frontier

Hy-Vee is looking closely at opportunities to be on the cutting edge of pharmacogenomics, the emerging area of treatment in which medications are tailored to individual genetic makeup.
CVS Health, Cook County Sheriff urge consumers to safely dispose medications

CVS Health and Cook County Sheriff Thomas Dart announced a joint effort to raise consumer awareness about the importance of safe medication disposal.
NACDS Foundation supports Project Lifeline's efforts to end opioid crisis

The National Association of Chain Drug Stores Foundation is collaborating with Project Lifeline to provide substance abuse screenings and referrals to at-risk patients in Pennsylvania.
Fresenius Kabi launches generic Trisenox

Fresenius Kabi's arsenic trioxide injection is the first-to-market generic of Teva's Trisenox, which is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia.
FDA green lights Shionogi's Xofluza

Xofluza is the first new antiviral flu treatment with a novel mechanism of action approved by the Food and Drug Administration in nearly 20 years.
VistaPharm intros generic Mepron unit-dose cups

VistaPharm is unveiling atovaquone oral suspension, which is the first generic of Mepron sachets, and used in the treatment of HIV.
Upsher-Smith launches generic Onfi

Upsher-Smith is introducing a generic version of Onfi tablets, which had a market value of $594 million, and Onfi oral suspension, which had a market value of $255 million for the year ended in August.